Low dose hydroxychloroquine prophylaxis for COVID-19 – a prospective study
Low dose hydroxychloroquine prophylaxis for COVID-19 – a prospective study
Abstract BackgroundSince the outbreak of COVID-19 pandemic, the world began a frantic search for possible prophylactic options. While trials on hydroxychloroquine (HCQ) prophylaxis are ongoing, concrete evidence is lacking. The study aimed to determine the relative efficacy of various doses of oral HCQ in prophylaxis and mitigating the severity of COVID-19 in healthcare workers. MethodsThis was a prospective cohort with four arms (high, medium, low dose, and control) of HCQ prophylaxis, used by healthcare workers at a tertiary care center in India. Participants were grouped as per their opting for any one arm on a voluntary basis as per institute policy under the Government guidance. The outcomes studied were COVID-19 positivity by RT-PCR and its severity assessed by WHO COVID-19 severity scale. ResultsTotal 486 participants were enrolled, of which 29 (6%) opted for low dose, 2 (<1%) medium dose, and none for high dose HCQ while 455 (93.6%) were in the control arm. Of the 164 participants who underwent RT-PCR, 96 (58.2%) tested positive. Out of these 96 positive cases, the majority of them (79 of 96 [82.3%]) were ambulatory and were managed conservatively at home. Only 17.7% (17 of 96) participants, all of them from the control group, required hospitalization with the mild-moderate disease. None of the participants had severe disease, COVID-related complications, ICU stay, or death. The difference in the outcome assessed amongst the various arms was statistically insignificant (p value >0.05). ConclusionThis single-center study demonstrated that HCQ prophylaxis in healthcare workers does not cause a significant reduction in COVID-19 as well as mitigating its severity in those infected. At present, most of the trials have not shown any benefit. The debate continues to rage, should HCQ prophylaxis be given to healthcare workers for chemoprophylaxis?
Gupta Arvind Kumar、Kant Ravi、RE-HCP2 COVID study group、Agarwal Mayank、Ranka Rajat、Sharma Suresh K、Walia Rohit、Dhar Minakshi、Sharma Prakhar、Mishra UB、Chikara Gaurav、Kumar Ajay、Samanta Ramanuj、Gupta Manoj Kumar、Bahurupi Yogesh Arvind、Panda Prasan Kumar、Negi Rizu、Saha Sarama
Department of Pathology, All India Institute of Medical Sciences (AIIMS)All India Institute of Medical Sciences (AIIMS)Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS)Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS)Department of Nursing, All India Institute of Medical Sciences (AIIMS)Department of Cardiology, All India Institute of Medical Sciences (AIIMS)Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS)Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS)Department of Hospital Affair, All India Institute of Medical Sciences (AIIMS)Department of Pharmacology, All India Institute of Medical Sciences (AIIMS)Department of Anesthesia and Critical Care, All India Institute of Medical Sciences (AIIMS)Department of Opthalmology, All India Institute of Medical Sciences (AIIMS)All India Institute of Medical Sciences (AIIMS)Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS)Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS)Department of Nursing, All India Institute of Medical Sciences (AIIMS)Department of Biochemistry, All India Institute of Medical Sciences (AIIMS)
预防医学医学研究方法医药卫生理论
ChemoprophylaxisCohort studyHealthcare workersSevere COVID-19
Gupta Arvind Kumar,Kant Ravi,RE-HCP2 COVID study group,Agarwal Mayank,Ranka Rajat,Sharma Suresh K,Walia Rohit,Dhar Minakshi,Sharma Prakhar,Mishra UB,Chikara Gaurav,Kumar Ajay,Samanta Ramanuj,Gupta Manoj Kumar,Bahurupi Yogesh Arvind,Panda Prasan Kumar,Negi Rizu,Saha Sarama.Low dose hydroxychloroquine prophylaxis for COVID-19 – a prospective study[EB/OL].(2025-03-28)[2025-04-24].https://www.medrxiv.org/content/10.1101/2021.09.13.21262971.点此复制
评论